- RASopathies Overview
- Syndromes
- RASopathy Clinicians Directory
- Scientific Meetings
- 2011 Symposium Abstracts
- A Drosophila Approach to Ras Pathway Disease
- A novel HRAS substitution (c.266C>G; p.S89C) resulting in decreased downstream signaling reveals a new dimension of RAS pathway dysregulation in human development
- A role for synaptic plasticity in the cognitive deficits of Costello syndrome mice
- Assessing Genotype-Phenotype Correlation in Costello Syndrome with the Use of a Severity Score
- Characterisation of Costello syndrome mutations in sperm and implications for genetic counselling
- Clinical pathways: the DYSCERNE experience
- Epidemiological Features of Costello and CFC Syndromes
- Epidemiological features of Costello Syndrome and Cardio-facio-cutaneous Syndrome: findings from the first nationwide survey
- Germline K-RasV14I mutation causes Noonan Syndrome and fatal myeloproliferative disorder
- Germline mutations of the CBL gene : a new RASopathie with predisposition to juvenile myelomonocytic leukemia (JMML)
- Growth Hormone Signaling
- Hematologic abnormalities associated with patients with cardio-facio-cutaneous syndrome
- Hematopoietic differentiation abnormalities in Noonan syndrome and Noonan/JMML iPS cells
- High-throughput drug screening to identify novel small molecules to rescue Noonan syndrome phenotypes in Drosophila
- How Loss of Neurofibromin in Oligodendrocytes Affects the Brain
- HRAS mutants identified in Costello syndrome patients can induce cellular senescence: possible implications for the pathogenesis of Costello syndrome
- Identification of novel genes critical to survival of malignant peripheral nerve sheath tumor cells via medium throughput screening using lenti-viral shRNA
- Induced pluripotent stem cell-derived cardiomyocytes as a model to study cardiac defects in Noonan syndrome and related disorders
- Lovastatin, a cholesterol-lowering medication, improves cognitive deficits in children with Neurofibromatosis type 1: Phase 1 study results
- Mechanisms underlying the cognitive deficits in animal models of rasopathies
- MODELING RASOPATHIES WITH HIPSC
- Molecular genetic analysis of the protein tyrosine phosphatase Shp2 (PTPN11) in the mouse telencephalon
- MOUSE MODELS OF COSTELLO SYNDROME
- N-myristoylation of SHOC2 and Mazzanti syndrome
- Neurodevelopmental Profiles for RASopathies
- Neurofibromatosis Networking – Building the Tools to Advance Research Discoveries to the Clinic
- Noonan syndrome-associated Raf1 mutants with increased or decreased kinase activity differentially activate Erk and cause distinct syndromic phenotypes
- NRAS mutations – a rare cause of Noonan syndrome
- NSEuroNet – a progress report about the European database
- Perinatal or Adult Nf1 Inactivation using Tamoxifen-inducible PlpCre Each Cause Neurofibroma Formation
- Piebaldism with Multiple Café-au-lait Macules and Intertriginous Freckling: Evidence for a Common Pathway between KIT and SPRED1
- Pro-hypertrophic signaling induced by the Shp2 mutation Q510E in mice
- Progeria, aging and translational medicine: from obscurity to treatment trials and beyond
- Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation
- Ras Pathway Biology: Hematopoiesis and Cancer
- Ras/MAPK Disorders: Genotype Phenotype Correlations
- 2013 UK rasopathies symposium
- 2015-symposium
- 2017 International RASopathies Symposium
- 2019 International Symposium
- 2021 Symposium Home Page
- 2023 Symposium Home Page
- 4th International RASopathies Symposium
- 5th International RASopathies Symposium
- 2011 Symposium Abstracts
- Publications
- Resources
- Webinars Library
- Family Forums
RASopathies
